Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | RGD Reference | Notes | Source | Original Reference(s) | ZNF30 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZNF30 mRNA | CTD | PMID:20106945 PMID:21632981 | ZNF30 | Human | 4,4'-sulfonyldiphenol | decreases methylation | EXP | | 6480464 | bisphenol S results in decreased methylation of ZNF30 gene | CTD | PMID:31601247 | ZNF30 | Human | acrolein | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of more ... | CTD | PMID:32699268 | ZNF30 | Human | actinomycin D | multiple interactions | EXP | | 6480464 | [Dactinomycin co-treated with nutlin 3] results in increased expression of ZNF30 mRNA | CTD | PMID:38460933 | ZNF30 | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of ZNF30 mRNA | CTD | PMID:21641981 | ZNF30 | Human | alpha-pinene | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of more ... | CTD | PMID:32699268 | ZNF30 | Human | antirheumatic drug | increases expression | EXP | | 6480464 | Antirheumatic Agents results in increased expression of ZNF30 mRNA | CTD | PMID:24449571 | ZNF30 | Human | atrazine | decreases expression | EXP | | 6480464 | Atrazine results in decreased expression of ZNF30 mRNA | CTD | PMID:22378314 | ZNF30 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of ZNF30 promoter | CTD | PMID:27901495 | ZNF30 | Human | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of ZNF30 5' UTR | CTD | PMID:27901495 | ZNF30 | Human | beta-lapachone | decreases expression | EXP | | 6480464 | beta-lapachone results in decreased expression of ZNF30 mRNA | CTD | PMID:38218311 | ZNF30 | Human | beta-lapachone | increases expression | EXP | | 6480464 | beta-lapachone results in increased expression of ZNF30 mRNA | CTD | PMID:38218311 | ZNF30 | Human | bisphenol A | decreases methylation | EXP | | 6480464 | bisphenol A results in decreased methylation of ZNF30 gene | CTD | PMID:31601247 | ZNF30 | Human | cadmium atom | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ZNF30 more ... | CTD | PMID:35301059 | ZNF30 | Human | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of ZNF30 mRNA | CTD | PMID:38568856 | ZNF30 | Human | cadmium dichloride | multiple interactions | EXP | | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ZNF30 more ... | CTD | PMID:35301059 | ZNF30 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ZNF30 gene] | CTD | PMID:28238834 | ZNF30 | Human | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of ZNF30 mRNA | CTD | PMID:27392435 | ZNF30 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of ZNF30 mRNA | CTD | PMID:27392435 | ZNF30 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of ZNF30 mRNA | CTD | PMID:20106945 | ZNF30 | Human | Dibutyl phosphate | affects expression | EXP | | 6480464 | di-n-butylphosphoric acid affects the expression of ZNF30 mRNA | CTD | PMID:37042841 | ZNF30 | Human | dicrotophos | decreases expression | EXP | | 6480464 | dicrotophos results in decreased expression of ZNF30 mRNA | CTD | PMID:28302478 | ZNF30 | Human | iron dichloride | decreases expression | EXP | | 6480464 | ferrous chloride results in decreased expression of ZNF30 mRNA | CTD | PMID:35984750 | ZNF30 | Human | Nutlin-3 | multiple interactions | EXP | | 6480464 | [Dactinomycin co-treated with nutlin 3] results in increased expression of ZNF30 mRNA | CTD | PMID:38460933 | ZNF30 | Human | ozone | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of more ... | CTD | PMID:32699268 | ZNF30 | Human | potassium chloride | multiple interactions | EXP | | 6480464 | [Dronabinol results in decreased susceptibility to Potassium Chloride] which results in decreased expression of ZNF30 more ... | CTD | PMID:29691375 | ZNF30 | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of ZNF30 mRNA | CTD | PMID:21632981 | ZNF30 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of ZNF30 mRNA | CTD | PMID:38568856 | ZNF30 | Human | temozolomide | increases expression | EXP | | 6480464 | Temozolomide results in increased expression of ZNF30 mRNA | CTD | PMID:31758290 | ZNF30 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of ZNF30 mRNA | CTD | PMID:37042841 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






















